Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69%; this number increased to 81% when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P < 0.001). Of the main therapies, PE frequently caused SE (19%), followed by steroids (12.5%) and IVIg (4%). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE. © 2009 EFNS.

A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy / Cocito, D; Paolasso, I; Antonini, G; Benedetti, L; Briani, C; Comi, C; Fazio, R; Jann, S; Mata, S; Mazzeo, S; Sabatelli, M; Nobile-Orazio, E; O. N., Behalf Of The Italian Network For Cidp Register; Grimaldi, S; Falcone, Y; Ciaramitaro, P; Cossa, Fm; Clemenzi, A; Garibaldi, M; Beronio, A; Schenone, A; Campagnolo, M; Dalla Torre, C; Fruguglietti, Me; Borsini, W; Conte, A; Luigetti, M; Gallia, F; Terenghi, F. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - STAMPA. - 17:2(2010), pp. 289-294. [10.1111/j.1468-1331.2009.02802.x]

A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy

Antonini, G;Clemenzi, A;Garibaldi, M;
2010

Abstract

Background and purpose: The guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) therapy suggest to use immunoglobulins (IVIg) and steroid as first-line therapies. Patients who do not respond to one of the two drugs should be switched to the other drug. We collected therapeutic outcome data in patients followed at 11 centres in order to document the clinical practice in Italy. Methods: Clinical and electrophysiological data of patients with CIDP were entered into a central database. The clinical outcome (Rankin Scale) and drug side effects (SE) for first- and second-line therapies were recorded. Results: A total of 267 patients were included. The percentage of responders (R) to first-line therapy [steroid or IVIg or plasma exchange (PE)] was 69%; this number increased to 81% when patients who switched to different therapies were included. Overall, the percentage of R to IVIg was similar to R to steroids (P = 0.07) and higher than R to PE (P < 0.001). Of the main therapies, PE frequently caused SE (19%), followed by steroids (12.5%) and IVIg (4%). Conclusions: Switching between traditional therapies increases the number of responder patients. IVIg was confirmed to be a therapy with low SE. © 2009 EFNS.
2010
chronic inflammatory demyelinating polyneuropathy; corticosteroids; immunoglobulins; immunosuppressant drugs; plasma exchange; therapy
01 Pubblicazione su rivista::01a Articolo in rivista
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy / Cocito, D; Paolasso, I; Antonini, G; Benedetti, L; Briani, C; Comi, C; Fazio, R; Jann, S; Mata, S; Mazzeo, S; Sabatelli, M; Nobile-Orazio, E; O. N., Behalf Of The Italian Network For Cidp Register; Grimaldi, S; Falcone, Y; Ciaramitaro, P; Cossa, Fm; Clemenzi, A; Garibaldi, M; Beronio, A; Schenone, A; Campagnolo, M; Dalla Torre, C; Fruguglietti, Me; Borsini, W; Conte, A; Luigetti, M; Gallia, F; Terenghi, F. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - STAMPA. - 17:2(2010), pp. 289-294. [10.1111/j.1468-1331.2009.02802.x]
File allegati a questo prodotto
File Dimensione Formato  
Cocito_nationwide-retrospective_2010.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 97.09 kB
Formato Adobe PDF
97.09 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/76491
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 110
  • ???jsp.display-item.citation.isi??? 96
social impact